“开塞露”厂商小方制药将申购:毛利率超65%,研发投入占比仅3.45%

“开塞露”厂商小方制药将申购:毛利率超65%,研发投入占比仅3.45%_腾讯新闻,小方制药,开塞露,医药行业,制药,国科天成,申购,毛利率,打新